By Anthony O. Goriainoff

 

AstraZeneca PLC said Wednesday that a combination of its Imfinzi immunotherapy with tremelimumab antibodies showed an unprecedented survival rate in liver-cancer patients.

The London-listed pharmaceutical company said results from its Himalaya Phase III trial showed a single dose of tremelimumab added to Imfinzi showed unprecedented survival in first-line unresectable liver cancer. It said that 31% of patients were alive at three years.

The company said that the combination--known as the STRIDE regimen--also showed no increase in severe liver toxicity and that no bleeding risk was observed.

Separately, AstraZeneca said Imfinzi plus chemotherapy reduced the risk of death by 20% in first-line advanced biliary tract cancer when compared with chemotherapy on its own.

"Positive results from the Topaz-1 Phase III trial showed AstraZeneca's Imfinzi, in combination with standard-of-care chemotherapy, demonstrated a statistically significant and clinically meaningful improvement in overall survival and progression-free survival versus chemotherapy alone as a 1st-line treatment for patients with advanced biliary tract cancer," the company said.

 

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

 

(END) Dow Jones Newswires

January 19, 2022 02:59 ET (07:59 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Astrazeneca Charts.